GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » 6-Month Price Index

Cadrenal Therapeutics (Cadrenal Therapeutics) 6-Month Price Index : 0.99 (As of Jun. 19, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-06-19), Cadrenal Therapeutics's 6-Month Price Index is 0.99.


Competitive Comparison of Cadrenal Therapeutics's 6-Month Price Index

For the Biotechnology subindustry, Cadrenal Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadrenal Therapeutics  (NAS:CVKD) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadrenal Therapeutics  (NAS:CVKD) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.


Cadrenal Therapeutics 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029